Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Sarcoma 1 Neoplasms 1 Metastatic Non-Squamous Non-Small Cell Lung Cancer 1 Melanoma 1 Lung Neoplasms 1 Lung Diseases 1 Liposarcoma 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Breast Neoplasms 1 Advanced Solid Tumors 1

Interventions

Ipilimumab 98 pembrolizumab 84 Nivolumab 82 aldesleukin 51 Cyclophosphamide 49 Interleukin-2 38 fludarabine phosphate 31 Vemurafenib 31 Dacarbazine 31 dabrafenib 29 trametinib 28 Temozolomide 26 fludarabine 25 CTLA-4 Antigen 18 Bevacizumab 18 Radiosurgery 15 Paclitaxel 15 Carboplatin 14 encorafenib 13 binimetinib 13 Introns 13 talimogene laherparepvec 12 Radiotherapy 12 Interferon alpha-2 12 spartalizumab 11 cobimetinib 10 atezolizumab 10 sargramostim 9 peginterferon alfa-2b 9 montanide ISA 51 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Melanoma × sitravatinib × Clear all

NCT05542342 2026-06-01

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

16 enrolled 14 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡